Latest papers

Update on pediatric psoriasis, Part 2: Therapeutic management.

Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.

Topical dermatological drug delivery: quo vadis?

A novel class of compounds with cutaneous wound healing properties.

Irritant and sensitizing potential of eight surfactants commonly used in skin cleansers: an evaluation of 105 patients.

Treatment of recalcitrant periungual warts with cimetidine in pediatrics.

Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism.

Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening.

Optimizing topical therapies for treating psoriasis: a consensus conference.

Infliximab-induced lichen planopilaris.

Allergic contact dermatitis to Elidel cream itself?

Autoimmune hepatitis in two psoriasis patients treated with inflixmab.

Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?

Topical delivery for the treatment of psoriasis.

Use of biologic agents in pediatric psoriasis.

Application of nanotechnology in cosmetics.

Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.

Methotrexate guidelines 2009?

Efficacy of 15% azelaic acid in psoriasis vulgaris: a randomized, controlled clinical trial.

How and when to use biologics in psoriasis.